Clinical trials: Primary IgA Nephropathy
Primary IgA Nephropathy
A Trial of HR19042 Capsule in Healthy Chinese Subjects
The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects.
- Trial name
- NCT04887532
- Testing
- HR19042 capsule
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Glomerulonephritis, IGA
Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy
Along structural IgA abnormalities, hyperproduction of IgA is thought to play a role in the pathogenesis of primary IgA nephropathy.
- Trial name
- NCT00521508
- Testing
- gene transcription and cytometry
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Primary IgA Nephropathy; Autoimmune Hepatitis
Relative Bioavailability Study of HR19042 in Healthy Subjects
This is a single-center, randomized, open-label, three-period, dual Latin square crossover study. Primary Objective： 1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release…
- Trial name
- NCT06922305
- Testing
- HR19042 Capsule, Tarpeyo®, Budenofalk®
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
IgA Nephropathy (IgAN)
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study
- Trial name
- NCT07886476
- Testing
- IBI3034, Telitacicept
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.